- Last Close 350.8
- Sector Healthcare
- Industry Biotechnology
- Investment Style Mid Growth
- Day Range 349.30 – 356.60
- Year Range 228.80 – 405.50
- Market Cap 19.4329 Bil
- Volume / Avg 52,162.0 / 67,388.1
- Price / Sales 77.93
- Price / Book 7.15
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis ARGX
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile ARGX
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.
Breda, 4811 AH, NLD
FAQs for argenx SE Stock
No. ARGX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ARGX’s market cap is 19.43 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ARGX’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ARGX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ARGX’s historical performance against its industry peers and the overall market.